{"id":458223,"date":"2021-03-15T22:19:53","date_gmt":"2021-03-16T02:19:53","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=458223"},"modified":"2021-03-15T22:19:53","modified_gmt":"2021-03-16T02:19:53","slug":"biohaven-announces-pricing-of-200-million-public-offering-of-common-shares","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/biohaven-announces-pricing-of-200-million-public-offering-of-common-shares\/","title":{"rendered":"Biohaven Announces Pricing Of $200 Million Public Offering Of Common Shares"},"content":{"rendered":"
\n

PR Newswire<\/p>\n<\/p><\/div>\n

\n

\n NEW HAVEN, Conn.<\/span>, March 15, 2021<\/span> \/PRNewswire\/ —\u00a0Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), a commercial\u2013stage biopharmaceutical company with a marketed drug for the acute treatment of migraine and a portfolio of innovative, late\u2013stage product candidates targeting neurological diseases, including rare disorders, today announced the pricing of its underwritten public offering of 2,686,409 of its common shares at a price to the public of $76.00<\/span> per share.\u00a0 In addition, Biohaven has granted the underwriter a 30-day option to purchase up to an additional 402,961 common shares at the public offering price, less underwriting discounts and commissions.\u00a0 The gross proceeds from the offering are expected to be approximately $200 million<\/span> before deducting underwriting discounts and commissions and estimated offering expenses payable by Biohaven.\u00a0 The offering is expected to close on March\u00a017, 2021, subject to satisfaction of customary closing conditions.<\/p>\n

\n

\n
\n \"(PRNewsfoto\/Biohaven
\n <\/a>\n <\/p>\n<\/p><\/div>\n

Goldman Sachs & Co. LLC is acting as the book-running manager of the offering.<\/p>\n

The offering is being made only by means of a prospectus supplement and the accompanying prospectus, copies of which, when available, may be obtained from the offices of Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, NY<\/span> 10282, telephone: 1\u2013866-471-2526, facsimile: 212-902-9316 or by emailing Prospectus-ny@ny.email.gs.com<\/a>.<\/p>\n

The shares will be issued pursuant to an effective shelf registration statement on Form S-3.\u00a0 Copies of the registration statement can be accessed through the SEC’s website at www.sec.gov<\/a>.\u00a0 This press release shall not constitute an offer to sell or a solicitation of an offer to buy any of these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the applicable securities laws of such state or jurisdiction.<\/p>\n

Contact<\/p>\n

Dr. Vlad Coric<\/span><\/p>\n

Chief Executive Officer<\/p>\n

Biohaven Pharmaceutical Holding Company Ltd.<\/p>\n

Phone: (203) 404-0410<\/p>\n

Email: vlad.coric@biohavenpharma.com<\/a><\/p>\n

\u00a0<\/p>\n

<\/div>\n

\n \"Cision\" View original content to download multimedia:http:\/\/www.prnewswire.com\/news-releases\/biohaven-announces-pricing-of-200-million-public-offering-of-common-shares-301247797.html<\/a><\/p>\n

SOURCE Biohaven Pharmaceutical Holding Company Ltd.<\/p>\n<\/p><\/div>\n

\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

PR Newswire NEW HAVEN, Conn., March 15, 2021 \/PRNewswire\/ —\u00a0Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), a commercial\u2013stage biopharmaceutical company with a marketed drug for the acute treatment of migraine and a portfolio of innovative, late\u2013stage product candidates targeting neurological diseases, including rare disorders, today announced the pricing of its underwritten public offering of 2,686,409 of its common shares at a price to the public of $76.00 per share.\u00a0 In addition, Biohaven has granted the underwriter a 30-day option to purchase up to an additional 402,961 common shares at the public offering price, less underwriting discounts and commissions.\u00a0 The gross proceeds from the offering are expected to be approximately $200 million before deducting underwriting discounts and commissions and estimated offering … <\/p>\n

Continue reading “Biohaven Announces Pricing Of $200 Million Public Offering Of Common Shares”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-458223","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nBiohaven Announces Pricing Of $200 Million Public Offering Of Common Shares - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/biohaven-announces-pricing-of-200-million-public-offering-of-common-shares\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Biohaven Announces Pricing Of $200 Million Public Offering Of Common Shares - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire NEW HAVEN, Conn., March 15, 2021 \/PRNewswire\/ —\u00a0Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), a commercial\u2013stage biopharmaceutical company with a marketed drug for the acute treatment of migraine and a portfolio of innovative, late\u2013stage product candidates targeting neurological diseases, including rare disorders, today announced the pricing of its underwritten public offering of 2,686,409 of its common shares at a price to the public of $76.00 per share.\u00a0 In addition, Biohaven has granted the underwriter a 30-day option to purchase up to an additional 402,961 common shares at the public offering price, less underwriting discounts and commissions.\u00a0 The gross proceeds from the offering are expected to be approximately $200 million before deducting underwriting discounts and commissions and estimated offering … Continue reading "Biohaven Announces Pricing Of $200 Million Public Offering Of Common Shares"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/biohaven-announces-pricing-of-200-million-public-offering-of-common-shares\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-03-16T02:19:53+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mma.prnewswire.com\/media\/413973\/Biohaven_Pharmaceutical_Holding_Company_Ltd_Logo.jpg\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biohaven-announces-pricing-of-200-million-public-offering-of-common-shares\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biohaven-announces-pricing-of-200-million-public-offering-of-common-shares\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Biohaven Announces Pricing Of $200 Million Public Offering Of Common Shares\",\"datePublished\":\"2021-03-16T02:19:53+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biohaven-announces-pricing-of-200-million-public-offering-of-common-shares\\\/\"},\"wordCount\":347,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biohaven-announces-pricing-of-200-million-public-offering-of-common-shares\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/413973\\\/Biohaven_Pharmaceutical_Holding_Company_Ltd_Logo.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biohaven-announces-pricing-of-200-million-public-offering-of-common-shares\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biohaven-announces-pricing-of-200-million-public-offering-of-common-shares\\\/\",\"name\":\"Biohaven Announces Pricing Of $200 Million Public Offering Of Common Shares - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biohaven-announces-pricing-of-200-million-public-offering-of-common-shares\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biohaven-announces-pricing-of-200-million-public-offering-of-common-shares\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/413973\\\/Biohaven_Pharmaceutical_Holding_Company_Ltd_Logo.jpg\",\"datePublished\":\"2021-03-16T02:19:53+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biohaven-announces-pricing-of-200-million-public-offering-of-common-shares\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biohaven-announces-pricing-of-200-million-public-offering-of-common-shares\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biohaven-announces-pricing-of-200-million-public-offering-of-common-shares\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/413973\\\/Biohaven_Pharmaceutical_Holding_Company_Ltd_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/413973\\\/Biohaven_Pharmaceutical_Holding_Company_Ltd_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biohaven-announces-pricing-of-200-million-public-offering-of-common-shares\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Biohaven Announces Pricing Of $200 Million Public Offering Of Common Shares\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Biohaven Announces Pricing Of $200 Million Public Offering Of Common Shares - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/biohaven-announces-pricing-of-200-million-public-offering-of-common-shares\/","og_locale":"en_US","og_type":"article","og_title":"Biohaven Announces Pricing Of $200 Million Public Offering Of Common Shares - Market Newsdesk","og_description":"PR Newswire NEW HAVEN, Conn., March 15, 2021 \/PRNewswire\/ —\u00a0Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), a commercial\u2013stage biopharmaceutical company with a marketed drug for the acute treatment of migraine and a portfolio of innovative, late\u2013stage product candidates targeting neurological diseases, including rare disorders, today announced the pricing of its underwritten public offering of 2,686,409 of its common shares at a price to the public of $76.00 per share.\u00a0 In addition, Biohaven has granted the underwriter a 30-day option to purchase up to an additional 402,961 common shares at the public offering price, less underwriting discounts and commissions.\u00a0 The gross proceeds from the offering are expected to be approximately $200 million before deducting underwriting discounts and commissions and estimated offering … Continue reading \"Biohaven Announces Pricing Of $200 Million Public Offering Of Common Shares\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/biohaven-announces-pricing-of-200-million-public-offering-of-common-shares\/","og_site_name":"Market Newsdesk","article_published_time":"2021-03-16T02:19:53+00:00","og_image":[{"url":"https:\/\/mma.prnewswire.com\/media\/413973\/Biohaven_Pharmaceutical_Holding_Company_Ltd_Logo.jpg","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biohaven-announces-pricing-of-200-million-public-offering-of-common-shares\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biohaven-announces-pricing-of-200-million-public-offering-of-common-shares\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Biohaven Announces Pricing Of $200 Million Public Offering Of Common Shares","datePublished":"2021-03-16T02:19:53+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biohaven-announces-pricing-of-200-million-public-offering-of-common-shares\/"},"wordCount":347,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biohaven-announces-pricing-of-200-million-public-offering-of-common-shares\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/413973\/Biohaven_Pharmaceutical_Holding_Company_Ltd_Logo.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biohaven-announces-pricing-of-200-million-public-offering-of-common-shares\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/biohaven-announces-pricing-of-200-million-public-offering-of-common-shares\/","name":"Biohaven Announces Pricing Of $200 Million Public Offering Of Common Shares - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biohaven-announces-pricing-of-200-million-public-offering-of-common-shares\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biohaven-announces-pricing-of-200-million-public-offering-of-common-shares\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/413973\/Biohaven_Pharmaceutical_Holding_Company_Ltd_Logo.jpg","datePublished":"2021-03-16T02:19:53+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biohaven-announces-pricing-of-200-million-public-offering-of-common-shares\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/biohaven-announces-pricing-of-200-million-public-offering-of-common-shares\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biohaven-announces-pricing-of-200-million-public-offering-of-common-shares\/#primaryimage","url":"https:\/\/mma.prnewswire.com\/media\/413973\/Biohaven_Pharmaceutical_Holding_Company_Ltd_Logo.jpg","contentUrl":"https:\/\/mma.prnewswire.com\/media\/413973\/Biohaven_Pharmaceutical_Holding_Company_Ltd_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biohaven-announces-pricing-of-200-million-public-offering-of-common-shares\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Biohaven Announces Pricing Of $200 Million Public Offering Of Common Shares"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/458223","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=458223"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/458223\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=458223"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=458223"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=458223"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}